StockData
Stevanato Group S.p.A. logo

Stevanato Group S.p.A. (STVN) stock

STVNNYSESurgical & Medical Instruments & Apparatus
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 4, 2026Score 8/30
$15.53−0.27 (-1.71%)

Close on Nov 16, 2026Market cap $4.70BP/E 27.6Yield –

Stevanato Group S.p.A. grew revenue 7.4% to €1.19B over fiscal 2025. Operating income rose 23.4% to €198.80M, moving the operating margin from 14.6% to 16.8%. Free cash flow was €22.32M. At the latest close the market valued the company at €4.26B, 27.6 times its earnings.

Revenue
€1.19B
+7.4% vs. a year earlier
Operating income
€198.80M
+23.4% vs. a year earlier
Free cash flow
€22.32M
FY2025
EPS, diluted
0.51 EUR
+18.6% vs. a year earlier

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025

Valuation

Market cap
€4.26B
P/E ratio
27.6
Price to sales
3.59
Price to book
2.87
Dividend yield
–
Free cash flow yield
0.52%

Fundamentals

Revenue
€1.19B
Net income
€139.84M
EPS, diluted
0.51 EUR
Free cash flow
€22.32M

Trading

Previous close
$15.80
Open
$15.57
Day's range
$15.12 – $15.90
Volume
1,083,259
Average volume (20 days)
1,273,784
RSI (14 days)
41.2
Volatility (1 year)
55.1%
Relative volume
1.93×

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodSTVNS&P 500DifferenceSTVN per yearS&P 500 per year
1 month-17.8%-3.1%−14.8 pts
3 months-26.3%-4.5%−21.8 pts
Year to date-22.5%+9.4%−31.9 pts
1 year-29.4%+11.3%−40.7 pts
3 years-41.0%+70.4%−111.4 pts-16.1%+19.4%
5 years-28.5%+68.6%−97.1 pts-6.5%+11.0%

Eight years at a glance

Fiscal years 2018 to 2025, EUR

Revenue

€1.19B+7.4% YoY

Gross profit

€343.88M+13.7% YoY

Operating income

€198.80M+23.4% YoY

Net income

€139.84M+18.7% YoY

EPS, diluted

0.51 EUR+18.6% YoY

Free cash flow

€22.32M
Reported period

Press releases

Releases Stevanato Group S.p.A. filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Stevanato Group S.p.A.

Surgical & Medical Instruments & Apparatus

Stevanato Group S.p.A. provides drug containment, drug delivery, and diagnostic solutions, alongside manufacturing engineering systems for the pharmaceutical, biotechnology, and life sciences industries. It operates through two primary segments: Biopharmaceutical and Diagnostic Solutions, which supplies products such as pre-fillable syringes, vials, cartridges, diagnostic consumables, and drug delivery devices; and Engineering, which designs visual inspection, assembly, packaging, and serialization machinery. The company primarily serves global pharmaceutical, biotechnology, and diagnostic businesses, supporting their drug product life cycles from research through commercial production.

Company profile, executives and history

Stevanato Group S.p.A. stock: common questions

What is Stevanato Group S.p.A.'s stock price?

STVN closed at $15.53 on Nov 16, 2026, down 1.71% on the day.

What is Stevanato Group S.p.A.'s market cap?

Stevanato Group S.p.A. was worth $4.70B at the close on Nov 16, 2026: the share price times the diluted shares outstanding.

What is STVN's P/E ratio?

STVN trades at 27.6 times earnings, based on diluted earnings per share of 0.51 EUR over fiscal 2025.

How much revenue does Stevanato Group S.p.A. make?

Stevanato Group S.p.A. reported revenue of €1.19B for fiscal 2025, up 7.4% from a year earlier.

Does Stevanato Group S.p.A. pay a dividend?

No. Stevanato Group S.p.A. has not paid a cash dividend over the last twelve months.

How has STVN stock performed over the past year?

Including dividends, STVN returned -29.4% over the past year, against +11.3% for the S&P 500.

Who are Stevanato Group S.p.A.'s competitors?

Companies most similar to Stevanato Group S.p.A. by business, industry and size include WST, MMSI, IART, EMBC, TFX.

See a number that looks wrong?